SynthesisScientific reports2026
Blood-based circulating microRNAs as diagnostic biomarkers in cutaneous melanoma: a systematic review and meta-analysis.
Synthesis in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the ever-increasing incidence of cutaneous melanoma (CM), early detection has become pivotal for ensuring patient survival. MicroRNAs (miRNAs) are promising diagnostic biomarkers owing to their stability and wide availability in various body fluids. This systematic review and meta-analysis evaluated the diagnostic performance of blood-based circulating free miRNAs and extracellular vesicle (EV)-derived miRNAs for CM. The study protocol was registered in PROSPERO (CRD420251125262). A total of 557 records were identified, with 11 studies included in the systematic review and 10 in the meta-analysis. Diagnostic performance was evaluated for all studies combined, and separately for individual miRNA and miRNA combinations. The bivariate model showed a pooled sensitivity of 0.86, specificity of 0.85, and diagnostic odds ratio (DOR) of 33.52. Separate analyses indicated that individual miRNAs yielded sensitivity, specificity, and DOR values of 0.80, 0.78, and 13.71, respectively. On the other hand, miRNA combinations achieved superior accuracy with a sensitivity of 0.91, specificity of 0.89, and DOR of 84.05. Subgroup analysis demonstrated that the plasma samples outperformed the other sample sources. Overall, circulating miRNAs exhibit strong potential as noninvasive diagnostic biomarkers for CM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.